Novavax Inc (NVAX) stock
Close on Nov 12, 2026Market cap $1.44BP/E –Yield –
Novavax Inc saw revenue fall 61.3% to $411.65M over the twelve months to Sep 30, 2026. Operating income fell 128.4% to -$87.39M, moving the operating margin from 28.9% to -21.2%. At the latest close the market valued the company at $1.44B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $1.44B
- P/E ratio
- –
- Price to sales
- 3.51
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $411.65M
- Net income
- -$76.73M
- EPS, diluted
- -$0.48
- Book value per share
- -$1.31
- Diluted shares
- 165M
Trading
- Next earnings
- Feb 25, 2027 (estimated, before the open)
- Previous close
- $9.98
- Open
- $9.70
- Day's range
- $8.75 – $9.74
- Volume
- 7,014,017
- Average volume (20 days)
- 6,491,418
- Index membership
- Russell 2000 (since Jun 2023), Russell 3000
- Beta (5 years)
- 1.93
- 52-week range
- $6.20 – $13.38
- RSI (14 days)
- 38.9
- Volatility (1 year)
- 73.5%
- Relative volume
- 1.23×
- WACC
- 14.5%
On 1 of our idea list: Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | NVAX | S&P 500 | Difference | NVAX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -30.8% | -2.7% | −28.1 pts | ||
| 3 months | +10.1% | -1.7% | +11.8 pts | ||
| Year to date | +30.4% | +11.9% | +18.5 pts | ||
| 1 year | +21.7% | +12.0% | +9.7 pts | ||
| 3 years | +40.4% | +78.2% | −37.8 pts | +12.0% | +21.2% |
| 5 years | -94.8% | +73.2% | −168.1 pts | -44.7% | +11.6% |
| 10 years | -68.5% | +309.6% | −378.1 pts | -10.9% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Novavax filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Results
- Results
- Results
About Novavax
Biological Products, (No Diagnostic Substances)
Novavax, Inc. is a biotechnology company focused on developing and commercializing vaccines to prevent serious infectious diseases. The company utilizes a proprietary recombinant protein nanoparticle technology combined with its Matrix-M adjuvant to stimulate immune responses. Its commercial and pipeline portfolio includes authorized coronavirus vaccines, malaria vaccines, and combination vaccine candidates such as COVID-19 and influenza formulations. Novavax collaborates with and licenses its technology to global pharmaceutical partners, healthcare organizations, and sovereign governments for vaccine manufacturing, distribution, and pipeline integration.
Company profile, executives and historyNovavax stock: common questions
What is Novavax's stock price?
NVAX closed at $8.76 on Nov 12, 2026, down 12.22% on the day. Over the past 52 weeks it traded between $6.20 and $13.38.
What is Novavax's market cap?
Novavax was worth $1.44B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is NVAX's P/E ratio?
Novavax lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.48), so it has no meaningful P/E ratio.
How much revenue does Novavax make?
Novavax reported revenue of $411.65M for the twelve months to Sep 30, 2026, down 61.3% from a year earlier.
Does Novavax pay a dividend?
No. Novavax has not paid a cash dividend over the last twelve months.
When does Novavax report earnings next?
Novavax is expected to report Q4 FY2026 results on Feb 25, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has NVAX stock performed over the past year?
Including dividends, NVAX returned +21.7% over the past year, against +12.0% for the S&P 500.
How many NVAX shares are sold short?
46M shares were sold short at the latest FINRA report, 30.93% of the float, or 7.6 days of average trading volume.
Who are Novavax's competitors?
Companies most similar to Novavax by business, industry and size include VXRT, MRNA, IMCR, VIR, SVA.
See a number that looks wrong?